Jacobs Medical Center

PrecisePK Celebrates 30 Years of Bayesian Precision Dosing Partnership With UC San Diego Health, Leading Other UC Hospitals To Follow

Retrieved on: 
Thursday, August 24, 2023
Partnership, Society, Infectious Diseases Society of America, Tacrolimus, Jacobs Medical Center, Rady Children's Hospital, Software, Infection, Survival, Society of Infectious Diseases Pharmacists, Cancer, UC San Diego Health, Pharmacokinetics, Staphylococcus aureus, AKI, Pharmacist, Aminoglycoside, Hospital, Vancomycin, UC, Guideline, Patient, Patient safety, SAN, AUC, Busulfan, Scripps Health, Pharmacology, Safety, American Society of Health-System Pharmacists, Pharmaceutical industry, Generic drug, Medical imaging, List of things named after Thomas Bayes

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.

Key Points: 
  • SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Today, PrecisePK announces the celebration of the 30th anniversary of its partnership with UC San Diego Health.
  • This decades-long initiative has proven the success of using Bayesian precision dosing to improve patient outcomes.
  • With other UC hospitals joining, PrecisePK is delivering state-of-the-art Bayesian therapeutic drug monitoring technology to a total of 9 prominent sites.
  • PrecisePK and UCSD Health mark 30 years of partnership in vancomycin AUC precision dosing, leading others to follow.

Livivos, Inc. Announces Award of NIH Grant for Its LiverScope® Device

Retrieved on: 
Tuesday, October 4, 2022
Steatosis, UC, University of California, San Diego, School, UCSD, UC San Diego Health, Claustrophobia, Liver disease, Research, Moores Cancer Center, Health, National Institute, UC San Diego School of Medicine, NIH, Digestive, FDA, SBIR, MRI, U.S. News & World Report, Translational Research Institute, Jacobs Medical Center, Kidney, National, Hospital Insurance and Diagnostic Services Act, Radiology, SAN, Cardiovascular disease, Biomarker, Liver, Patient, Diagnosis, Innovation, Fatty liver disease, University, UC San Diego Medical Center, Hillcrest, Organization, NIDDK, Diabetes, GLOBE, National Institute of Diabetes and Digestive and Kidney Diseases, News, Pharmaceutical industry, Medical imaging

Currently, fatty liver disease can be diagnosed with MRI scanners, but these are expensive, bulky, require dedicated shielded rooms and trained technicians, and can induce claustrophobia in patients.

Key Points: 
  • Currently, fatty liver disease can be diagnosed with MRI scanners, but these are expensive, bulky, require dedicated shielded rooms and trained technicians, and can induce claustrophobia in patients.
  • "We are excited to be working with the NIDDK and our UC San Diego collaborators, who are the country's leading experts on liver imaging."
  • Livivos is introducing its LiverScope, an innovative, Point-of-Care liver disease diagnostic device that has the potential to revolutionize how the disorder is detected, graded, and managed.
  • Dr. Claude Sirlin of UCSD serves as an advisor to Livivos, Inc. and holds stock in the company.

Changing the World Through Philanthropy: UC San Diego Raises $3.05 Billion as Campaign for UC San Diego Concludes

Retrieved on: 
Thursday, July 14, 2022
Scripps Institution of Oceanography, Student, Multimedia, Empathy, Campaign, SVKM's NMIMS, Patient, Trustee, SAN, Jacobs Medical Center, Research, UC, UC San Diego Health, Compassion, University, Rady School of Management, Doctor of Philosophy, Cabinet, Renewable energy, Pharmaceutical industry, Oceanography

SAN DIEGO, July 14, 2022 /PRNewswire/ -- The University of California San Diego has reached the conclusion of its landmark Campaign for UC San Diego, raising a total of $3.05 billion in philanthropic support over a span of 10 years. The funds have spurred a significant campus transformation, increased access with scholarships and fellowships for the next generation of leaders and expanded the university's positive global impact with research that is addressing some of the world's most pressing concerns.

Key Points: 
  • Founded in 1960, UC San Diego is the nation's youngest university to reach a multibillion-dollar fundraising goal in a single campaign, raising $1 billion more than the original $2 billion goal.
  • More than 163,000 supporters designated charitable gifts and grants to over 450 different areas across campus, including UC San Diego Health and Scripps Institution of Oceanography.
  • Campaign for UC San Diego volunteer leadership played a critical role in the success of the Campaign.
  • In addition, more than 100 alumni and community members stepped up to lead this historic effort as members of the Campaign for UC San Diego Cabinet.

A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021

Retrieved on: 
Friday, November 12, 2021
Research, General Health, Professional Services, Pharmaceutical, Oncology, Venture Capital, Genetics, Clinical Trials, Science, Surgery, Biotechnology, Health, SITC, Observational study, MD, Neoplasm, MD Anderson Cancer Center, CGMP, Regent, Washington Convention Center, LOH, Cancer immunotherapy, Society, Principal, Tempus, MSLN, Ronald Reagan UCLA Medical Center, Annual general meeting, Section 32, Jacobs Medical Center, NYU, Walter, Society for Immunotherapy of Cancer, CEA, Immunotherapy, HLA, StepStone Group, Patient, CAR, NYU Langone Health, Walter E. Washington Convention Center, Pharmaceutical industry, Medical imaging

A2 Bio today announced the first presentation of its Tmod platform; a powerful, precise targeting system controlled by tumor deletions which transforms CEA and MSLN CAR T cells into tumor-selective agents.

Key Points: 
  • A2 Bio today announced the first presentation of its Tmod platform; a powerful, precise targeting system controlled by tumor deletions which transforms CEA and MSLN CAR T cells into tumor-selective agents.
  • Preclinical results demonstrate how Tmod primary T cells selectively kill tumor cells mixed with normal cells in vitro, and display robust activity in vivo.
  • CEA Tmod cells selectively kill tumor cells within the same mouse implanted with established normal and tumor xenografts.
  • MSLN Tmod constructs show similar selectivity, illustrating the breadth and modularity of the Tmod platform.

A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021

Retrieved on: 
Friday, November 12, 2021
SITC, View, Observational study, MD, Neoplasm, MD Anderson Cancer Center, CGMP, Regent, Washington Convention Center, LOH, Cancer immunotherapy, Society, Multimedia, Principal, Tempus, MSLN, Ronald Reagan UCLA Medical Center, Annual general meeting, Section 32, Jacobs Medical Center, NYU, Walter, Society for Immunotherapy of Cancer, CEA, Immunotherapy, HLA, StepStone Group, Patient, CAR, NYU Langone Health, Walter E. Washington Convention Center, Pharmaceutical industry, Medical imaging

A2 Bio today announced the first presentation of its Tmod platform; a powerful, precise targeting system controlled by tumor deletions which transforms CEA and MSLN CAR T cells into tumor-selective agents.

Key Points: 
  • A2 Bio today announced the first presentation of its Tmod platform; a powerful, precise targeting system controlled by tumor deletions which transforms CEA and MSLN CAR T cells into tumor-selective agents.
  • Preclinical results demonstrate how Tmod primary T cells selectively kill tumor cells mixed with normal cells in vitro, and display robust activity in vivo.
  • CEA Tmod cells selectively kill tumor cells within the same mouse implanted with established "normal" and tumor xenografts.
  • MSLN Tmod constructs show similar selectivity, illustrating the breadth and modularity of the Tmod platform.

California Protons Is Now Affiliated With UC San Diego Health Cancer Network

Retrieved on: 
Tuesday, June 25, 2019
Health, Hospitals, Radiology, Oncology, Health, Cancer, UC San Diego Health, Medicine, Jacobs Medical Center, Moores Cancer Center, NCI-designated Cancer Center, Proton therapy, Oncology, University of California, San Diego, Prostate cancer, UC San Diego School of Medicine, UC San Diego Health, California Protons Cancer Therapy Center

As of May 2019, California Protons Cancer Therapy Center is now affiliated with UC San Diego Health Cancer Network, giving more patients access to world-class, lifesaving proton therapy treatment provided by radiation oncologists from Moores Cancer Center at UC San Diego Health, San Diegos only National Cancer Institute-Designated Comprehensive Cancer Center.

Key Points: 
  • As of May 2019, California Protons Cancer Therapy Center is now affiliated with UC San Diego Health Cancer Network, giving more patients access to world-class, lifesaving proton therapy treatment provided by radiation oncologists from Moores Cancer Center at UC San Diego Health, San Diegos only National Cancer Institute-Designated Comprehensive Cancer Center.
  • We are excited to be affiliated with UC San Diego Health Cancer Network, in addition to Rady Childrens Hospital, enabling us to utilize our services and premier technology to help even more people with cancer.
  • California Protons and UC San Diego Health will work together on research to further support protocols for breast cancer, prostate cancer, head and neck cancers, and more.
  • UC San Diego Health is comprised of UC San Diego Medical Center, Jacobs Medical Center, Shiley Eye Institute and Sulpizio Cardiovascular Center, as well as other primary and specialty practices located throughout Southern California.